Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Lidofenin→

Lidofenin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
59160-29-1
Molecular formula
C14H18N2O5
Molecular weight
294.3 g/mol
Drug class
Diagnostic radiopharmaceutical ligandiminodiacetic-acid hepatobiliary imaging agent when radiolabelled
Mechanism of action
Lidofenin is a hepatobiliary iminodiacetic-acid ligand that, when labelled with technetium-99m, is taken up by hepatocytes and excreted into bile. The radiolabel permits scintigraphic visualisation of hepatic uptake, biliary transit and gallbladder filling.
Indications / reported uses
  • Used as technetium Tc-99m lidofenin (HIDA) for hepatobiliary scintigraphy to evaluate hepatocyte function, bile flow, gallbladder filling and selected biliary disorders. The imaging agent is the technetium-labelled preparation.

Sources: https://www.ncbi.nlm.nih.gov/mesh/68019780 · https://www.ncbi.nlm.nih.gov/books/NBK538243/ · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Lidofenin Environmental Risk Assessment (ERA) (the Lidofenin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.